Reviewer's report

Title: Phase II Study of Olaparib in Patients with Refractory Ewing Sarcoma Following Failure of Standard Chemotherapy

Version: 2 Date: 14 August 2014

Reviewer: Richard HH Quek

Reviewer's report:

I enjoyed reading this well written manuscript. The authors should be congratulated for conducting this academic study in a rare cohort of patients translating a sound biological hypothesis into a proof-of-concept clinical trial.

Minor Essential Revisions

Statistical design and methods

1. Was pathology centrally reviewed. If it was, could the authors include this information into the manuscript

Results

1. Line 173 mentioned there were 6 occurrences of grade 3 AEs but table 2 indicated 4 events. Were there events not captured in the table (i.e. selected toxicities) or were there recurrent events in the same patient. Please clarify

Discretionary Revisions

1. Could the authors include the period of study accrual.

2. Could the authors provide more information about the grade 4 event encountered in this study

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests